A New Medication for ADHD on the Horizon
Psychologists may have a promising new ADHD medication option to prescribe: mazindol CR. Mazindol CR, also known as NLS-1, is a treatment produced by the Switzerland-based company, NLS Pharma. It would be a revolutionary addition to the ADHD medicine cabinet because unlike current options on the market, mazindol CR is a non-stimulant. Many patients do not take well to stimulant medications, such as methylphenidate or amphetamine. Pending successful completion of the last stage of testing, NLS-1 could open up a new door for countless people with ADHD symptoms.
Let’s look at the numbers from the Phase II part of the trial*:
● 85 adults with ADHD took part in a double-blind, placebo controlled trial for 6 weeks
● 55 percent of participants taking NLS-1 said their symptoms decreased by at least 50 percent
● 70 percent of participants taking NLS-1 said their symptoms decreased by at least 30 percent
● Less than 25 percent of participants taking the placebo reported a 30 percent or greater improvement, making the results statistically significant
● Benefits were experienced within 1 week, which is ⅙ of the time other non-stimulants take to activate
The results also mentioned that the side-effects were “very-well tolerated”, although it was unclear exactly what the side-effects are, or the quantity of them. Nonetheless, the trial showed exciting results that may change the way psychologists prescribe medicinal ADHD treatments.
*NLS Pharma, 2017. NLS PHARMA UNVEILS POSITIVE PHASE 2 DATA FOR NLS-1 (MAZINDOL CR) IN ADULTS WITH ADHD, DEMONSTRATING SIGNIFICANT IMPROVEMENT IN SYMPTOMS. Stans/Switzerland & Miami. Web. source
The Pathways team of professionals has helped thousands of people with brain injuries. We are Dedicated to effective and compassionate care for individuals with neurological challenges.
